Rockwell Medical (RMTI) Competitors

Rockwell Medical (NASDAQ:RMTI) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Do institutionals and insiders hold more shares of RMTI or ARAY?

23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 1.9% of Rockwell Medical shares are owned by company insiders. Comparatively, 4.2% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media refer more to RMTI or ARAY?

In the previous week, Accuray had 3 more articles in the media than Rockwell Medical. MarketBeat recorded 5 mentions for Accuray and 2 mentions for Rockwell Medical. Rockwell Medical's average media sentiment score of 1.43 beat Accuray's score of 0.45 indicating that Rockwell Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rockwell Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accuray	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger valuation & earnings, RMTI or ARAY?

Rockwell Medical has higher earnings, but lower revenue than Accuray. Rockwell Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$83.61M	0.82	-$8.44M	-$0.05	-42.40
Accuray	$446.55M	0.50	-$15.55M	-$0.17	-13.18

Do analysts recommend RMTI or ARAY?

Rockwell Medical currently has a consensus price target of $6.00, indicating a potential upside of 183.02%. Accuray has a consensus price target of $9.00, indicating a potential upside of 301.79%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Rockwell Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Accuray	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, RMTI or ARAY?

Rockwell Medical has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Is RMTI or ARAY more profitable?

Rockwell Medical has a net margin of -1.25% compared to Accuray's net margin of -3.72%. Rockwell Medical's return on equity of 8.55% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-1.25%	8.55%	3.80%
Accuray	-3.72%	-36.93%	-3.52%

Does the MarketBeat Community prefer RMTI or ARAY?

Accuray received 21 more outperform votes than Rockwell Medical when rated by MarketBeat users. Likewise, 65.61% of users gave Accuray an outperform vote while only 57.70% of users gave Rockwell Medical an outperform vote.

Company	Underperform	Outperform
Rockwell Medical	Outperform Votes 311 57.70%	Underperform Votes 228 42.30%
Accuray	Outperform Votes 332 65.61%	Underperform Votes 174 34.39%

Summary

Rockwell Medical and Accuray tied by winning 9 of the 18 factors compared between the two stocks.